Related Experiment Videos
Is medical therapy an expensive way for delaying surgery in BPH patients?
F Di Silverio1, A Sciarra, S Di Nicola
1Department of Urology, University of Rome La Sapienza, Rome.
Insights
Delayed medical therapy can postpone surgery for benign prostatic hyperplasia (BPH) but isn't suitable for all patients. Patient characteristics and disease progression significantly influence the choice between medical management and transurethral resection of the prostate (TURP).
Area of Science:
- Urology
- Gerontology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) management often necessitates surgical intervention.
- Pharmacologic approaches may delay the need for surgery in select BPH patients.
- Transurethral resection of the prostate (TURP) remains a primary surgical option.
Purpose of the Study:
- To evaluate the role of delayed medical therapy in BPH management.
- To identify patient subgroups benefiting from delayed medical therapy versus immediate surgery.
- To determine factors influencing the therapeutic decision-making process in BPH.
Main Methods:
- Review of current literature on BPH treatment strategies.
- Analysis of factors influencing BPH progression and patient outcomes.
- Investigation into the role of growth factors in BPH natural history.
Main Results:
- Delayed medical therapy is not universally applicable for all BPH patients.
- Patient age, health status, and comorbidities (e.g., diabetes, hypertension) are critical decision factors.
- The natural history and progression rate of BPH influence therapeutic choices.
Conclusions:
- The decision for delayed medical therapy or immediate TURP in BPH depends on individual patient characteristics and disease progression.
- Young, healthy patients may benefit from delayed therapy based on clinical BPH stage.
- Worsening health status or significant comorbidities may warrant immediate surgical intervention for BPH.
Abstract:
Nowadays, no medical therapy can be considered as a real and definitive alternative to surgery in the management of BPH patients. We considered pharmacologic approach as a treatment that may delay the need for surgery for BPH. In some cases a delayed therapy may continue for all patient life, excluding the need for TURP. The questions that we propose in the present review are: Is there always a role for a delayed medical therapy in the treatment of BPH patients? In which BPH patients a delayed medical therapy and in which instead an immediate surgery may be chosen? Which factors may influence this decision? A delayed medical therapy cannot be chosen in all BPH cases. Two factors can influence the evolution of the disease and the decision of the therapy: the first, natural history of BPH is related to BPH progression, and the second to patient characteristics. The role of growth factors in the natural history of BPH is investigated. Age of patient, his health condition and the presence of concomitant diseases are characteristics that may influence the therapeutic choice. In a young patient with good health condition and no concomitant diseases, the specific clinical phase of BPH is crucial to determinate the need for surgery of for medical delayed therapy. If there is a worsening health status or concomitant diseases as diabetes and hypertension that can increase the risk related to surgery in the future or can determine a more rapid evolution of BPH, TURP may be immediately recommended in all clinical phases of prostatic hyperplasia. The role of age in this therapeutic decision must be carefully examined.